Panobinostat, also known as NVP LBH-589 or LBH-589, is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. On 2/23/2015, it received FDA accelerated approval for use in patients with multiple myeloma who had received at least 2 previous treatments, including bortezomib and an immunomodulatory agent.
Chen, Shanwen & Zhang, Peiming & Chen, Huali & Yu, Yu & Gan, Zongjie. (2018). An Improved and Efficient Synthesis of Panobinostat. Journal of Chemical Research. 42. 471-473. 10.3184/174751918X15357309308931.
Bair, Kenneth Walter; Green, Michael A.; Perez, Lawrence B.; Remiszewski, Stacy W.; Sambucetti, Lidia; Versace, Richard William; Sharma, Sushil Kumar. Preparation of hydroxamic acids as deacetylase inhibitors. WO 2002022577. (Assignee Novartis AG, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft mbH; Novartis Pharma GmbH)
Chen, Ying-Nan Pan; Lassota, Peter; Wood, Alexander Wallace. Cyclooxygenase-2 inhibitor-histone deacetylase inhibitor combination for treatment of premalignant colon lesions, colon cancer, and other malignancies. WO 2003039599. (Assignee Novartis AG, Switz.; Novartis Pharma Gmbh)
Lassota, Piotr. Rapid method for screening compounds for in vivo activity. WO 2002055742. (Assignee Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Novartis Pharma Gmb)
Izumo, Seigo; Shetty, Suraj Shivappa. Preparation of cinnamic acid N-hydroxy amides as histone deacetylase inhibitors for the treatment of pathologic cardiac hypertrophy and heart failure. WO 2007021682. (Assignee Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.)
Acemoglu, Murat; Bajwa, Joginder S.; Parker, David John; Slade, Joel. Process for preparation of (2E)-N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide. WO 2007146718. (Assignee Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.)
Siripragada, Mahender Rao; Vohra, Irfan; Parikh, Chirag; Buddh, Mayur; Joshi, Akash; Thirunavakarasu, Ananda Babu; Parikh, Pinky. Preparation of novel salts and polymorphic forms of Panobinostat. WO 2017221163. (Assignee Alembic Pharmaceuticals Limited, India)
Xu, Yongxiang. Synthesis of Panobinostat and intermediates. CN 106674079. (Assignee Nanjing Cavendish Bio-Engineering Technology Co., Ltd., Peop. Rep. China)
Gan, Zongjie. Panobinostat intermediate, its synthesis and application. CN 108794375. (Assignee Chongqing University of Medical Sciences, Peop. Rep. China)
Liu, Qian; Jiang, Jianan; Ji, Yafei. Synthesis of panobinostat. Zhongguo Yiyao Gongye Zazhi. Volume 42. Issue 10. Pages 725-727. (2011).
